Overview

Safety Study for Beta Thalassemia Subjects on PTG-300

Status:
Completed
Trial end date:
2020-07-31
Target enrollment:
0
Participant gender:
All
Summary
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Protagonist Therapeutics
Protagonist Therapeutics, Inc.
Criteria
Inclusion Criteria:

- NTD and TD β-thalassemia subjects who completed Week 12 and Week 16 respectively in
Study PTG-300-02.

Exclusion Criteria:

- Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and
Week 16 in TD).